erlotinib + irinotecan + panitumumab

This is a combination regimen consisting of three agents: - **Erlotinib** is a small molecule tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR), blocking its intracellular tyrosine kinase activity and thereby inhibiting downstream signaling pathways involved in tumor cell proliferation and survival. - **Irinotecan** is a small molecule chemotherapeutic agent, specifically a topoisomerase I inhibitor. It interferes with DNA replication in cancer cells by stabilizing the complex between topoisomerase I and DNA, leading to DNA damage and cell death. - **Panitumumab** is a fully human monoclonal antibody that binds to the extracellular domain of EGFR, preventing ligand binding (such as EGF or TGF-alpha) and subsequent receptor activation. This blocks EGFR-mediated signal transduction, resulting in reduced tumor cell proliferation, increased apoptosis, and decreased angiogenesis. The rationale for combining these agents lies in dual inhibition of EGFR through both extracellular blockade (panitumumab) and intracellular kinase inhibition (erlotinib), potentially enhancing anti-tumor effects. Irinotecan adds cytotoxic activity via its distinct mechanism. This combination has been studied primarily for metastatic colorectal cancer (mCRC), particularly in patients with wild-type RAS tumors[3][4][6]. Clinical trials have explored this regimen as second-line or salvage therapy after progression on standard treatments.